Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
PDF 5kWORD 18k
9 February 2018
Answer given by Mr Andriukaitis on behalf of the Commission
Question reference: E-007489/2017

In accordance with Article 168 of the Treaty on the Functioning of the European Union(1), the Union action shall respect the responsibilities of the Member States for the definition of their health policy and for the organisation and delivery of health services and medical care, including the allocation of the resources assigned to them.

In the context of the European Stability Mechanism stability support programme, the Greek authorities are therefore called to implement measures to improve the efficiency of the health system, thereby its sustainability, with the specifics of the measures entirely for the authorities to decide.

EU legislation does not allow for specific tools to influence the availability of medicines on the market of a Member State as a consequence of its national pricing policy and hence the Commission has no legal means to prevent companies from withdrawing products from the market or not marketing products in all Member States.

In the specific context of shortages, the Commission is collaborating with the Member States, the Heads of Medicines Agencies and the European Medicines Agency in order to share best practices with a view to assuring continuous supply of medicines through effective implementation of Article 81 of Directive 2001/83/EC(2).


Last updated: 7 June 2018Legal notice